...
首页> 外文期刊>Journal of molecular cell biology >Adiponectin, the past two decades.
【24h】

Adiponectin, the past two decades.

机译:脂联素,近二十年来。

获取原文
获取原文并翻译 | 示例
           

摘要

Adiponectin is an adipocyte-specific factor, first described in 1995. Over the past two decades, numerous studies have elucidated the physiological functions of adiponectin in obesity, diabetes, inflammation, atherosclerosis, and cardiovascular disease. Adiponectin, elicited through cognate receptors, suppresses glucose production in the liver and enhances fatty acid oxidation in skeletal muscle, which together contribute to a beneficial metabolic action in whole body energy homeostasis. Beyond its role in metabolism, adiponectin also protects cells from apoptosis and reduces inflammation in various cell types via receptor-dependent mechanisms. Adiponectin, as a fat-derived hormone, therefore fulfills a critical role as an important messenger to communicate between adipose tissue and other organs. A better understanding of adiponectin actions, including the pros and cons, will advance our insights into basic mechanisms of metabolism and inflammation, and potentially pave the way toward novel means of pharmacological intervention to address pathophysiological changes associated with diabetes, atherosclerosis, and cardiometabolic disease.
机译:脂联素是一种脂肪细胞特异性因子,于1995年首次描述。在过去的二十年中,大量研究阐明了脂联素在肥胖,糖尿病,炎症,动脉粥样硬化和心血管疾病中的生理功能。通过关联受体诱发的脂联素抑制肝脏中的葡萄糖生成,并增强骨骼肌中的脂肪酸氧化,共同促进全身能量稳态中的有益代谢作用。脂联素除了在新陈代谢中的作用外,还通过受体依赖性机制保护细胞免于凋亡,并减轻各种细胞类型的炎症。因此,脂联素作为一种脂肪来源的激素,起着至关重要的作用,它是在脂肪组织和其他器官之间进行交流的重要信使。对脂联素作用的更好理解,包括利弊,将使我们对代谢和炎症的基本机制有更深入的了解,并有可能为寻求新的药理干预手段铺平道路,以应对与糖尿病,动脉粥样硬化和心脏代谢性疾病相关的病理生理变化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号